

# Antibody-Mediated Graft Rejection - Pipeline Insight, 2020

<https://marketpublishers.com/r/A0F5E2613CACEN.html>

Date: February 2020

Pages: 106

Price: US\$ 1,500.00 (Single User License)

ID: A0F5E2613CACEN

## Abstracts

This report can be delivered to the clients within 48-72 Hours

### Antibody-Mediated Graft Rejection Overview

'Antibody-Mediated Graft Rejection Pipeline Insight, 2020' Report By DelveInsight Outlays Comprehensive Insights Of Present Clinical Development Scenario And Growth Prospects Across The Antibody-Mediated Graft Rejection Market. A Detailed Picture Of The Antibody-Mediated Graft Rejection Pipeline Landscape Is Provided, Which Includes The Disease Overview And Antibody-Mediated Graft Rejection Treatment Guidelines.

The Assessment Part Of The Report Embraces In-Depth Antibody-Mediated Graft Rejection Commercial Assessment And Clinical Assessment Of The Antibody-Mediated Graft Rejection Pipeline Products From The Pre-Clinical Developmental Phase To The Marketed Phase.

In The Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, Antibody-Mediated Graft Rejection Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related Details.

Antibody-Mediated Graft Rejection Of Pipeline Development Activities

The Report Provides Insights Into:

All Of The Companies That Are Developing Therapies For The Treatment Of Antibody-Mediated Graft Rejection With Aggregate Therapies Developed By Each Company For The Same.

Different Therapeutic Candidates Segmented Into Early-Stage, Mid-Stage And Late Stage Of Development For The Antibody-Mediated Graft Rejection Treatment.

Antibody-Mediated Graft Rejection Key Players Involved In Targeted Therapeutics Development With Respective Active And Inactive (Dormant Or Discontinued) Projects.

Drugs Under Development Based On The Stage Of Development, Route Of Administration, Target Receptor, Monotherapy Or Combination Therapy, A Different Mechanism Of Action, And Molecular Type.

Detailed Analysis Of Collaborations (Company-Company Collaborations And Company-Academia Collaborations), Licensing Agreement And Financing Details For Future Advancement Of Antibody-Mediated Graft Rejection Market.

The Report Is Built Using Data And Information Traced From The Researcher's Proprietary Databases, Company/University Websites, Clinical Trial Registries, Conferences, SEC Filings, Investor Presentations, And Featured Press Releases From Company/University Web Sites And Industry-Specific Third-Party Sources, Etc.

## Antibody-Mediated Graft Rejection Analytical Perspective By DelveInsight

In-Depth Antibody-Mediated Graft Rejection Commercial Assessment Of Products

This Report Provides A Comprehensive Commercial Assessment Of Therapeutic Drugs That Have Been Included, Which Comprises Of Collaborations, Licensing, And Acquisition Deal Value Trends. The Report Also Covers Company-Company Collaborations (Licensing/Partnering), Company-Academia Collaborations, And Acquisition Analysis In Both Graphical And Tabulated Form In A Detailed Manner.

Antibody-Mediated Graft Rejection Clinical Assessment Of Products

The Report Comprises Of Comparative Clinical Assessment Of Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type Across This Indication.

## **SCOPE OF THE REPORT**

The Antibody-Mediated Graft Rejection Report Provides An Overview Of Therapeutic Pipeline Activity And Therapeutic Assessment Of The Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type For Antibody-Mediated Graft Rejection Across The Complete Product Development Cycle, Including All Clinical And Nonclinical Stages.

It Comprises Of Detailed Profiles Of Antibody-Mediated Graft Rejection Therapeutic Products With Key Coverage Of Developmental Activities, Including Technology, Collaborations, Licensing, Mergers And Acquisition, Funding, Designations And Other Product-Related Details

Detailed Antibody-Mediated Graft Rejection Research And Development Progress And Trial Details, Results Wherever Available, Are Also Included In The Pipeline Study.

Coverage Of Dormant And Discontinued Pipeline Projects Along With The Reasons If Available Across Antibody-Mediated Graft Rejection.

## **REPORT HIGHLIGHTS**

A Better Understanding of Disease Pathogenesis Contributing To The Development Of Novel Therapeutics For Antibody-Mediated Graft Rejection.

In The Coming Years, The Antibody-Mediated Graft Rejection Market Is Set To Change Due To The Rising Awareness Of The Disease, And Incremental Healthcare Spending Across The World; Which Would Expand The Size Of The Market To Enable The Drug Manufacturers To Penetrate More Into The Market.

The Companies And Academics That Are Working To Assess Challenges And Seek Opportunities That Could Influence Antibody-Mediated Graft Rejection R&D. The Therapies Under Development Are Focused On Novel Approaches To Treat/Improve The Disease Condition.

A Detailed Portfolio of Major Pharma Players Who Are Involved In Fueling The Antibody-Mediated Graft Rejection Treatment Market. Several Potential Therapies For Antibody-Mediated Graft Rejection Are Under Investigation. With The Expected Launch Of These Emerging Therapies, It Is Expected That There Will Be A Significant Impact On The Antibody-Mediated Graft Rejection Market Size In The Coming Years.

Our In-Depth Analysis Of The Pipeline Assets (In Early-Stage, Mid-Stage And Late Stage Of Development For The Treatment Of Antibody-Mediated Graft Rejection ) Includes Therapeutic Assessment And Comparative Analysis. This Will Support The Clients In The Decision-Making Process Regarding Their Therapeutic Portfolio By Identifying The Overall Scenario Of The Research And Development Activities.

## KEY QUESTIONS

What Are The Current Options For Antibody-Mediated Graft Rejection Treatment?

How Many Companies Are Developing Therapies For The Treatment Of Antibody-Mediated Graft Rejection?

What Are The Principal Therapies Developed By These Companies In The Industry?

How Many Therapies Are Developed By Each Company For The Treatment Of Antibody-Mediated Graft Rejection?

How Many Antibody-Mediated Graft Rejection Emerging Therapies Are In Early-Stage, Mid-Stage, And Late Stage Of Development For The Treatment Of Antibody-Mediated Graft Rejection?

Out Of Total Pipeline Products, How Many Therapies Are Given As A Monotherapy And In Combination With Other Therapies?

What Are The Key Collaborations (Industry-Industry, Industry-Academia), Mergers And Acquisitions, And Major Licensing Activities That Will Impact

Antibody-Mediated Graft Rejection Market?

Which Are The Dormant And Discontinued Products And The Reasons For The Same?

What Is The Unmet Need For Current Therapies For The Treatment Of Antibody-Mediated Graft Rejection?

What Are The Recent Novel Therapies, Targets, Mechanisms Of Action And Technologies Developed To Overcome The Limitation Of Existing Antibody-Mediated Graft Rejection Therapies?

What Are The Clinical Studies Going On For Antibody-Mediated Graft Rejection And Their Status?

What Are The Results Of The Clinical Studies And Their Safety And Efficacy?

What Are The Key Designations That Have Been Granted For The Emerging Therapies For Antibody-Mediated Graft Rejection?

How Many Patents Are Granted And Pending For The Emerging Therapies For The Treatment Of Antibody-Mediated Graft Rejection?

## Contents

### **1. REPORT INTRODUCTION**

### **2. ANTIBODY-MEDIATED GRAFT REJECTION**

- 2.1. Overview
- 2.2. History
- 2.3. Antibody-Mediated Graft Rejection Symptoms
- 2.4. Causes
- 2.5. Pathophysiology
- 2.6. Antibody-Mediated Graft Rejection Diagnosis
  - 2.6.1. Diagnostic Guidelines

### **3. ANTIBODY-MEDIATED GRAFT REJECTION CURRENT TREATMENT PATTERNS**

- 3.1. Antibody-Mediated Graft Rejection Treatment Guidelines

### **4. ANTIBODY-MEDIATED GRAFT REJECTION - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE**

- 4.1. In-depth Commercial Assessment
  - 4.1.1. Antibody-Mediated Graft Rejection companies collaborations, Licensing, Acquisition -Deal Value Trends
    - 4.1.1.1. Assessment Summary
  - 4.1.2. Antibody-Mediated Graft Rejection Collaboration Deals
    - 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    - 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
    - 4.1.2.3. Antibody-Mediated Graft Rejection Acquisition Analysis

### **5. THERAPEUTIC ASSESSMENT**

- 5.1. Clinical Assessment of Pipeline Drugs
  - 5.1.1. Assessment by Phase of Development
  - 5.1.2. Assessment by Product Type (Mono / Combination)
    - 5.1.2.1. Assessment by Stage and Product Type
  - 5.1.3. Assessment by Route of Administration
    - 5.1.3.1. Assessment by Stage and Route of Administration
  - 5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

## **6. ANTIBODY-MEDIATED GRAFT REJECTION LATE STAGE PRODUCTS (PHASE-III)**

## **7. ANTIBODY-MEDIATED GRAFT REJECTION MID STAGE PRODUCTS (PHASE-II)**

## **8. EARLY STAGE PRODUCTS (PHASE-I)**

## **9. PRE-CLINICAL PRODUCTS AND DISCOVERY STAGE PRODUCTS**

## **10. INACTIVE PRODUCTS**

## **11. DORMANT PRODUCTS**

## **12. ANTIBODY-MEDIATED GRAFT REJECTION DISCONTINUED PRODUCTS**

## **13. ANTIBODY-MEDIATED GRAFT REJECTION PRODUCT PROFILES**

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

Detailed information in the report?

## **14. ANTIBODY-MEDIATED GRAFT REJECTION KEY COMPANIES**

## **15. ANTIBODY-MEDIATED GRAFT REJECTION KEY PRODUCTS**

## **16. DORMANT AND DISCONTINUED PRODUCTS**

### 16.1. Dormant Products

#### 16.1.1. Reasons for being dormant

### 16.2. Discontinued Products

#### 16.2.1. Reasons for the discontinuation

## **17. ANTIBODY-MEDIATED GRAFT REJECTION UNMET NEEDS**

## **18. ANTIBODY-MEDIATED GRAFT REJECTION FUTURE PERSPECTIVES**

## **19. ANTIBODY-MEDIATED GRAFT REJECTION ANALYST REVIEW**

## **20. APPENDIX**

## **21. REPORT METHODOLOGY**

### 21.1. Secondary Research

### 21.2. Expert Panel Validation



## List Of Tables

### LIST OF TABLES

- Table 1: Antibody-Mediated Graft Rejection Diagnostic Guidelines
- Table 2: Antibody-Mediated Graft Rejection Treatment Guidelines
- Table 3: Assessment Summary
- Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
- Table 5: Antibody-Mediated Graft Rejection Acquisition Analysis
- Table 6: Assessment by Phase of Development
- Table 7: Assessment by Product Type (Mono / Combination)
- Table 8: Assessment by Stage and Product Type
- Table 9: Assessment by Route of Administration
- Table 10: Assessment by Stage and Route of Administration
- Table 11: Assessment by Molecule Type
- Table 12: Assessment by Stage and Molecule Type
- Table 13: Assessment by MOA
- Table 14: Assessment by Stage and MOA
- Table 15: Assessment by Target
- Table 16: Assessment by Stage and Target
- Table 17: Antibody-Mediated Graft Rejection Late Stage Products (Phase-III)
- Table 18: Antibody-Mediated Graft Rejection Mid Stage Products (Phase-II)
- Table 19: Antibody-Mediated Graft Rejection Early Stage Products (Phase-I)
- Table 20: Pre-clinical and Discovery Stage Products
- Table 21: Inactive Products
- Table 22: Dormant Products
- Table 23: Discontinued Products

## List Of Figures

### LIST OF FIGURES

- Figure 1: Disease Overview
- Figure 2: History
- Figure 3: Symptoms
- Figure 4: Causes
- Figure 5: Pathophysiology
- Figure 6: Diagnostic Guidelines
- Figure 7: Treatment Guidelines
- Figure 8: Antibody-Mediated Graft Rejection companies collaborations, Licensing, Acquisition -Deal Value Trends
- Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
- Figure 10: Antibody-Mediated Graft Rejection Acquisition Analysis
- Figure 11: Assessment by Phase of Development
- Figure 12: Assessment by Product Type (Mono / Combination)
- Figure 13: Assessment by Stage and Product Type
- Figure 14: Assessment by Route of Administration
- Figure 15: Assessment by Stage and Route of Administration
- Figure 16: Assessment by Molecule Type
- Figure 17: Assessment by Stage and Molecule Type
- Figure 18: Assessment by MOA
- Figure 19: Assessment by Stage and MOA
- Figure 20: Late Stage Products (Phase-III)
- Figure 21: Mid Stage Products (Phase-II)
- Figure 22: Early Stage Products (Phase-I)
- Figure 23: Pre-clinical and Discovery Stage Products
- Figure 24: Inactive Products
- Figure 25: Dormant Products
- Figure 26: Discontinued Products
- Figure 27: Unmet Needs

## I would like to order

Product name: Antibody-Mediated Graft Rejection - Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/A0F5E2613CACEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A0F5E2613CACEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970